Zhejiang Tianyu Pharmaceutical Co., Ltd. (300702.SZ)
CNY 17.41
(0.58%)
CNY 17.41
(0.58%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 2.52 Billion | 2.66 Billion | 2.54 Billion | 2.58 Billion | 2.11 Billion | 1.46 Billion |
| Cost of Revenue | 1.67 Billion | 1.97 Billion | 1.61 Billion | 1.25 Billion | 926.4 Million | 876.26 Million |
| Gross Profit | 849.83 Million | 687.54 Million | 932.8 Million | 1.33 Billion | 1.18 Billion | 590.68 Million |
| Operating Expenses | 919.3 Million | 647.11 Million | 697.12 Million | 579.85 Million | 476.97 Million | 361.81 Million |
| Selling, General and Administrative Expenses | 178.75 Million | 173.93 Million | 172.05 Million | 138.42 Million | 159.3 Million | 130.96 Million |
| Research and Development Expenses | 243.82 Million | 231.1 Million | 227.4 Million | 179.06 Million | 112.25 Million | 79.45 Million |
| Other Expenses | 496.72 Million | -8.67 Million | -21.67 Million | -6.86 Million | 7.78 Million | -23.17 Million |
| Cost and Expenses | 2.45 Billion | 2.62 Billion | 2.3 Billion | 1.83 Billion | 1.4 Billion | 1.23 Billion |
| Operating Income | 145.83 Million | -101.83 Million | 240.08 Million | 775.74 Million | 688.31 Million | 195.75 Million |
| Interest Expense | 51.24 Million | 33.84 Million | 16.32 Million | 4.41 Million | 12.19 Million | 19.37 Million |
| Income Tax Expense | 44.55 Million | 8.44 Million | 13.73 Million | 101.81 Million | 98.37 Million | 25.64 Million |
| Earnings before Tax | 77.13 Million | -110.5 Million | 218.4 Million | 768.87 Million | 684.1 Million | 189.3 Million |
| Net Income | 27.35 Million | -118.95 Million | 204.67 Million | 667.06 Million | 585.72 Million | 163.66 Million |
| Earnings Per Share Basic | 0.08 | -0.34 | 0.59 | 2.06 | 1.80 | 0.51 |
| Earnings Per Share Diluted | 0.08 | -0.34 | 0.59 | 2.05 | 1.79 | 0.51 |
| Weighted Average Shares Outstanding | 341.99 Million | 345.57 Million | 346.9 Million | 323.81 Million | 325.56 Million | 323.72 Million |
| Weighted Average Shares Outstanding (Diluted) | 341.99 Million | 345.57 Million | 346.9 Million | 325.39 Million | 327.42 Million | 323.72 Million |
| Gross Margin | 0.34 | 0.26 | 0.37 | 0.52 | 0.56 | 0.40 |
| EBIT Margin | 0.17 | 0.11 | 0.19 | 0.34 | 0.39 | 0.21 |
| Profit Margin | 0.01 | -0.04 | 0.08 | 0.26 | 0.28 | 0.11 |
| EBITDA | 435.22 Million | 187.13 Million | 431.99 Million | 911.45 Million | 801.65 Million | 291.47 Million |
| Earnings Before Tax Margin | 0.06 | -0.04 | 0.09 | 0.30 | 0.33 | 0.13 |
| Breakdown | 2024 Q3 | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 FY | 2023 Q3 |
|---|---|---|---|---|---|---|
| Revenue | 666.8 Million | 569.89 Million | 682.89 Million | 662.31 Million | 2.52 Billion | 518.57 Million |
| Cost of Revenue | 429.75 Million | 393.36 Million | 445.89 Million | 419.1 Million | 1.53 Billion | 307.03 Million |
| Gross Profit | 237.04 Million | 176.52 Million | 236.99 Million | 243.2 Million | 990.04 Million | 211.53 Million |
| Operating Expenses | 181.57 Million | 165.82 Million | 163.9 Million | 219.89 Million | 673.71 Million | 138.27 Million |
| Selling, General and Administrative Expenses | 253.11 Million | 87.59 Million | 101.27 Million | -78.42 Million | - | 187.69 Million |
| Research and Development Expenses | 62.67 Million | 59.99 Million | 50.05 Million | 62.68 Million | - | 58.81 Million |
| Other Expenses | -134.2 Million | -18.24 Million | -12.57 Million | 5.1 Million | 1.16 Million | -224.72 Thousand |
| Cost and Expenses | 611.33 Million | 559.19 Million | 609.8 Million | 639 Million | 2.21 Billion | 445.3 Million |
| Operating Income | 38.33 Million | 10.69 Million | 73.09 Million | -30.04 Million | 70.74 Million | -576.31 Thousand |
| Interest Expense | 13.88 Million | 12.74 Million | 14.23 Million | 14.68 Million | 49.9 Million | 12.15 Million |
| Income Tax Expense | 6.22 Million | -4.02 Million | 19.41 Million | 16.5 Million | 44.55 Million | -1.48 Million |
| Earnings before Tax | 38.11 Million | 9.85 Million | 60.72 Million | -24.93 Million | 71.91 Million | -801.03 Thousand |
| Net Income | 31.89 Million | 12.69 Million | 40.51 Million | -41.43 Million | 27.35 Million | 683.02 Thousand |
| Earnings Per Share Basic | 0.09 | 0.04 | 0.12 | -0.12 | - | 0.00 |
| Earnings Per Share Diluted | 0.09 | 0.04 | 0.12 | -0.12 | - | 0.00 |
| Weighted Average Shares Outstanding | 343.92 Million | 343.92 Million | 345.57 Million | 345.57 Million | 341.99 Million | 345.57 Million |
| Weighted Average Shares Outstanding (Diluted) | 343.92 Million | 343.92 Million | 345.57 Million | 345.57 Million | 341.99 Million | 345.57 Million |
| Gross Margin | 0.36 | 0.31 | 0.35 | 0.37 | 0.39 | 0.41 |
| EBIT Margin | 0.08 | 0.16 | 0.12 | 0.01 | - | 0.11 |
| Profit Margin | 0.05 | 0.02 | 0.06 | -0.06 | 0.01 | 0.00 |
| EBITDA | 52 Million | 92.82 Million | 80.47 Million | 8.46 Million | - | 56.28 Million |
| Earnings Before Tax Margin | 0.06 | 0.02 | 0.11 | -0.05 | 0.03 | -0.00 |
3652
688318
HGH
CLEN
AMPG
IEM